Tags : Rigel Pharmaceuticals
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it Life sciences companies are putting all of their efforts into finding a treatment or developing a vaccine for this disease PharmaShots is keeping a track of all of the important updates in the Life-sciences […]Read More
Shots: Rigel to receive $30M upfront, $297.5M milestones including $20M on EMA approval of fostamatinib and royalties up to 30% on net sales. Grifols to get exclusive rights for fostamatinib in all indications including chronic ITP, autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN), in EU and Turkey Rigel will retain all global rights for […]Read More
Shots: The approval is based on three FIT studies results assessing Tavalisse (100/150mg, bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1 The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%) Tavalisse (fostamatinib disodium hexahydrate, PO) is a spleen tyrosine […]Read More
